Drug Profile
Beclometasone hydrofluoroalkane intranasal - Teva
Alternative Names: BDP HFA Nasal Aerosol; Beclometasone HFA intranasal - Teva; Beclomethasone HFA intranasal - Teva; Beclomethasone hydrofluoroalkane intranasal - Teva; Qnasl; Qnaze™Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Teva Pharmaceutical Industries
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 19 Dec 2014 Registered for Seasonal allergic rhinitis and Perennial allergic rhinitis (In children) in USA (Intranasal)
- 07 Nov 2014 Efficacy & adverse events data from a phase III trial in Perennial allergic rhinitis (in children aged 4-11 years) presented at the 71st Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2014)
- 13 May 2014 Preregistration for Perennial allergic rhinitis and Seasonal allergic rhinitis (in children aged 4-11 years) in USA (Intranasal)